Selenium Supplements: What the Evidence Says About Benefits and Risks

Official reviews describe selenium as part of 25 human selenoproteins and note that supplementation usually does not further raise key biomarkers unless status is low. EFSA also based adequacy largely on the point where selenoprotein P levels plateau, with no clear evidence of added health benefit above sufficiency. NIH Office of Dietary Supplements — Selenium Fact Sheet; EFSA — Dietary Reference Values for Selenium

The strongest randomized evidence argues against routine selenium use for cancer prevention. The 2018 Cochrane review found no reduction in overall cancer incidence or mortality, and the large SELECT trial using 200 mcg/day L-selenomethionine found no prevention benefit for prostate cancer or other major cancers. PubMed — Cochrane review on selenium and cancer prevention; PubMed — SELECT trial results

Meta-analytic evidence found that selenium alone, commonly studied at 100 to 400 mcg/day, did not reduce cardiovascular disease risk or cardiovascular mortality. This weakens the common idea that selenium should be taken routinely for heart protection in otherwise well-nourished adults. PubMed — Meta-analysis on selenium antioxidants and cardiovascular outcomes

Several reviews report reductions in thyroid peroxidase antibodies in Hashimoto thyroiditis, but the clinical relevance remains uncertain. A separate review found insufficient evidence for meaningful improvement in TSH, ultrasound findings or quality of life, so patient-important outcomes remain unresolved. PubMed — Review on selenium in chronic autoimmune thyroiditis; PubMed — Systematic review on selenium and Hashimoto thyroiditis; PubMed — 2024 randomized-trial synthesis

A recent meta-analysis reported improved clinical activity scores and orbitopathy-related quality of life in mild Graves orbitopathy. However, the SeGOSS trial in a selenium-sufficient population did not improve the primary quality-of-life outcome at 6 months, suggesting that baseline status may determine whether benefit appears. PubMed — Meta-analysis on selenium in Graves orbitopathy; PubMed — SeGOSS randomized trial

A common belief is that because selenium supports antioxidant enzymes, higher intake must provide broader protection. The reviewed evidence does not support that idea. In selenium-replete adults, extra selenium has not shown reliable cancer-prevention, cardiovascular or general wellness benefits, so “more is better” is not an evidence-based claim. PubMed — Cochrane review on selenium and cancer prevention; PubMed — SELECT trial results; PubMed — Meta-analysis on selenium and cardiovascular disease

Selenium clearly matters to thyroid biology, but that does not mean it reliably treats thyroid disorders. Some studies show lower thyroid antibody levels in Hashimoto thyroiditis, yet symptom improvement, thyroid hormone control and quality-of-life gains are much less certain. Even in Graves orbitopathy, benefit may depend on starting selenium status. NIH Office of Dietary Supplements — Selenium Fact Sheet; PubMed — Review on selenium in chronic autoimmune thyroiditis; PubMed — Systematic review on selenium and Hashimoto thyroiditis; PubMed — Meta-analysis on selenium in Graves orbitopathy; PubMed — SeGOSS randomized trial

Marketing claims about heavy-metal detox, joint maintenance or assured fertility improvement go beyond the evidence reviewed here. EFSA did not substantiate selenium claims for heavy-metal protection or normal joints, and fertility evidence often focuses on semen markers rather than pregnancy or live birth, which remain unconvincing. EFSA — Opinion on selenium health claims; European Commission — EU Register of Health Claims; PubMed — Review on selenium and male fertility outcomes

Selenium is physiologically important because it is incorporated into selenoproteins involved in oxidative balance, thyroid hormone conversion, immune processes and reproduction. That broad biological reach explains why selenium deficiency can matter clinically. Historical deficiency syndromes such as Keshan disease and Kashin-Beck disease showed that low selenium exposure can have serious consequences in certain regions. In current practice, however, the main relevance is that deficiency is real but unevenly distributed rather than universal. Higher-risk groups described in the reviewed sources include people living in low-selenium areas, people on long-term hemodialysis and people living with HIV. NIH Office of Dietary Supplements — Selenium Fact Sheet

This context changes how supplementation should be interpreted. In populations that already meet selenium needs, extra supplementation often does not improve important outcomes. The reviewed material emphasizes that biomarkers such as selenoprotein P may plateau once adequacy is reached, meaning additional intake may increase exposure without producing measurable benefit. This status-dependent pattern is one of the clearest themes across the article and helps explain why results from lower-selenium settings do not always translate to North American or other selenium-replete populations. NIH Office of Dietary Supplements — Selenium Fact Sheet; EFSA — Dietary Reference Values for Selenium; Linus Pauling Institute — Selenium

Selenium intake from food is harder to predict than intake of many other minerals because crop content reflects local soil selenium and animal foods reflect feed practices. Foods such as grains, meat, seafood, eggs, dairy and nuts can contribute meaningfully, but Brazil nuts are an especially important special case because they may contain very large and variable amounts. That makes them both a rich food source and a practical toxicity risk when consumed frequently alongside supplements. For many adults, usual dietary intake already meets needs before a dedicated selenium product is added. Linus Pauling Institute — Selenium; NIH Office of Dietary Supplements — Selenium Fact Sheet; EFSA — Upper Intake Level for Selenium

Supplement form also affects pharmacokinetics. Common forms include L-selenomethionine, selenium-enriched yeast, sodium selenite and sodium selenate. Organic forms often raise blood selenium more effectively, while sodium selenate is absorbed very efficiently but may be excreted more readily, and sodium selenite may be less well absorbed yet handled differently in the body. The key caution from the source article is that better bioavailability does not automatically mean better clinical benefit. The SELECT trial used L-selenomethionine, a commercially relevant form, and still did not show cancer-prevention benefit in a large selenium-replete population. Linus Pauling Institute — Selenium; PubMed — Oral ADME review of selenium compounds; PubMed — SELECT trial results

Selenium was once widely promoted as a general anti-cancer nutrient because of its antioxidant functions and earlier observational signals. The stronger randomized evidence reviewed here did not confirm that promise. The 2018 Cochrane review found no reduction in overall cancer incidence, cancer mortality or major site-specific cancers in low-risk-of-bias trials. SELECT, which randomized 35,533 men to 200 mcg/day L-selenomethionine or placebo, likewise found no reduction in prostate cancer or other prespecified cancers. For consumers, this is one of the clearest negative findings in the literature: routine selenium supplementation is not supported as a general cancer-prevention strategy in selenium-replete adults. PubMed — Cochrane review on selenium and cancer prevention; PubMed — SELECT trial results

A similar pattern appears in cardiovascular research. Because selenium participates in antioxidant systems, heart-protective effects sounded plausible mechanistically. Yet meta-analytic data did not show consistent reductions in cardiovascular disease or cardiovascular mortality with selenium supplementation, typically in the 100 to 400 mcg/day range. This gap between biologic plausibility and disappointing clinical outcomes is a recurring theme in the selenium literature and supports a more cautious interpretation of routine wellness marketing. PubMed — Meta-analysis on selenium antioxidants and cardiovascular outcomes; NIH Office of Dietary Supplements — Selenium Fact Sheet

Selenium has a clear biologic connection to thyroid function because deiodinase enzymes and thyroid antioxidant systems depend on it. That makes thyroid-focused supplementation plausible and helps explain why this is the most discussed area in the supplement market. In Hashimoto thyroiditis, several reviews and meta-analyses report reductions in thyroid peroxidase antibody levels after supplementation. However, the article stresses that antibody changes are surrogate markers, not the same as improved symptoms, better thyroid hormone control, improved ultrasound findings or reduced medication need. Those patient-important outcomes remain inconsistent or insufficiently documented. NIH Office of Dietary Supplements — Selenium Fact Sheet; PubMed — Review on selenium in chronic autoimmune thyroiditis; PubMed — Systematic review on selenium and Hashimoto thyroiditis; PubMed — 2024 randomized-trial synthesis

Mild Graves orbitopathy stands out as one of the more plausible niche uses. Meta-analytic evidence suggests improvements in clinical activity score and orbitopathy-specific quality of life, and earlier European thinking has often been comparatively favorable in this setting. Even here, though, the SeGOSS randomized trial complicates the picture by showing no significant primary quality-of-life benefit at 6 months in a selenium-sufficient population. The practical interpretation from the source article is that baseline status probably matters, so positive findings from relatively low-selenium settings should not be generalized automatically to everyone. PubMed — Meta-analysis on selenium in Graves orbitopathy; PubMed — SeGOSS randomized trial

Selenium is unusual in that the gap between enough and too much is relatively narrow. The source article highlights that the US adult upper limit is 400 mcg/day, whereas EFSA now uses a substantially lower adult upper limit of 255 mcg/day, with alopecia identified as the critical adverse effect. This means a 200 mcg supplement may appear conservative under one framework but sit much closer to the European safety ceiling once normal dietary intake is included. Trials and reviews also report higher rates of alopecia and dermatitis in some supplementation settings, reinforcing that toxicity is not merely theoretical. EFSA — Upper Intake Level for Selenium; NIH Office of Dietary Supplements — Selenium Fact Sheet; PubMed — Cochrane review on selenium and cancer prevention

Additional caution comes from metabolic and long-term safety signals. A systematic review and meta-analysis reported an approximately 11 percent increase in diabetes risk in experimental studies and higher risk at higher circulating selenium levels, although causality is not fully settled. The Denmark PRECISE trial also raised concern that 300 mcg/day taken over years may increase all-cause mortality. Combined with the real-world problem of additive intake from multivitamins, separate selenium products, fortified foods and Brazil nuts, these findings support the article’s main safety message: selenium should be used cautiously, with attention to total exposure rather than any single product label. PubMed — Meta-analysis on selenium exposure and type 2 diabetes; PubMed — Denmark PRECISE trial follow-up; EFSA — Upper Intake Level for Selenium